Regulatory Compliance Requirements for Molecular Diagnostic Kit Registration and Observations on Trends in the In Vitro Diagnostics Industry

I. Registration Classification and Regulatory Framework

Molecular diagnostic kits are regulated in mainland China as medical devices or in vitro diagnostic reagents, with classification management implemented based on product risk levels. Nucleic acid detection reagents for pathogens, tumor-related gene detection reagents, and similar products are typically classified into higher management categories and require registration applications to the drug regulatory authority. The filing or registration pathway depends on the specific intended use and risk level of the product. Enterprises should clarify the product category at the early stage of research and development, and conduct design and development, performance studies, and registration submissions in accordance with corresponding regulations and technical guidelines.

II. Core Content of Technical Review

During the registration review process, technical departments typically focus on the source of raw materials, reaction system design, analytical performance, stability, and methods for determining cutoff values or reference intervals. Enterprises need to submit complete research data demonstrating key performance characteristics of the kit, such as analytical sensitivity, analytical specificity, precision, and accuracy. For products involving gene mutations or single nucleotide polymorphisms, the basis for site selection and clinical significance must also be explained. The review emphasizes the authenticity, completeness, and traceability of technical data, rather than providing absolute guarantees for any specific performance parameter.

III. Quality Management System and Production Control

The production of molecular diagnostic kits should establish a quality system compliant with Good Manufacturing Practice for Medical Devices, covering design and development, procurement, production, inspection, sales, and after-sales service. Key raw materials such as primers, probes, enzymes, and dNTPs require supplier management and incoming inspection standards. Critical processes during production, such as formulation, aliquoting, lyophilization, or packaging, should be validated and maintained under stable environmental conditions. Finished product testing typically includes appearance, fill volume, nucleic acid amplification performance, and negative/positive quality control, but specific items shall be executed according to product technical requirements.

IV. Clinical Evaluation and Post-Market Surveillance

Molecular diagnostic kits generally require clinical evaluation before registration, verifying clinical performance through comparison with marketed similar products or clinical reference standards. Clinical evaluation should follow corresponding guidelines to ensure reasonable sample size, inclusion criteria, and statistical methods. After market launch, enterprises must also conduct adverse event monitoring and product complaint analysis, and take corrective and preventive actions or recalls when necessary. Post-market data helps continuously improve product quality, but any improvements must not arbitrarily alter the approved registration content and should be filed for changes according to regulations.

V. Industry Trends: Automation and Multiplex Multi-Target Testing

The current in vitro diagnostic industry shows trends toward automation, intelligence, and multiplex multi-target testing. Molecular diagnostic kits are increasingly adapted to fully automated nucleic acid extraction and amplification integrated systems, achieving "sample in, result out" with reduced manual intervention. Multiplex multi-target products can simultaneously detect multiple pathogens or gene loci in a single reaction, improving detection efficiency, and are suitable for scenarios requiring rapid differential diagnosis such as respiratory tract infections and bloodstream infections. However, multiplex design also increases the difficulty of system optimization and quality control, requiring attention to the balance of multiplex amplification and cross-reactivity during performance verification.

VI. Cold Chain Management and Supply Chain Resilience

Since molecular diagnostic kits often contain biologically active components such as enzymes, cold chain transportation and storage are important links in ensuring product quality. Enterprises need to establish temperature monitoring, deviation handling, and contingency plans to ensure products comply with label requirements during distribution. As industry specialization deepens, some enterprises are exploring lyophilization processes or room-temperature stabilization technologies to reduce dependence on cold chains. Such technologies are still evolving, and specific stability shall be subject to the instructions for use and registration approval documents. Overall, compliance capability, quality stability, and supply chain resilience will become key factors in the market competition of molecular diagnostic kits.